Drug Profile
TKS 1225
Alternative Names: TKS1225Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Imperial Innovations
- Developer Pfizer
- Class Anorectics; Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Obesity in United Kingdom (SC, Injection)
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 18 Dec 2008 Thiakis has been acquired and merged into Wyeth